Boehringer Ingelheim and Microsoft have launched a strategic collaboration to explore AI in clinical research, starting with lung health studies. The focus is on digital patient twins, computer-based models of individual patients built from clinical data, to test whether they can forecast disease progression and patient outcomes. The companies will assess whether these models can serve as synthetic or hybrid control arms, potentially reducing the number of participants in control groups, streamlining trial design and speeding up evidence generation. If successful, the approach could improve drug development efficiency and allow more trial participants to receive experimental treatments. The alliance also covers data centre modernisation and technical security, with further joint initiatives under review in animal health and commercial processes.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
MSFTartificial intelligencepharmaceuticalshealthcare
Open a keyword to see other news on the same topic.
Related tickers and likely impact
MSFT
• NeutralMicrosoft
Relevance: low
| Market | US stocks |
|---|---|
| Sector | Information Technology |
| Industry | Systems Software |
| Market cap | $4.0T |
| Close on 10/22/2026 | 521.58 |
| Change that session | -2.13% |
Impact is scored by AI from the headline and may be wrong. It is not investment advice.
Related news
- Healthcare and Life Sciences Leaders Build on NVIDIA to Advance Drug Discovery and Expand Patient Care
NVIDIA and the UW Medicine Institute for Protein Design debuted RFD4-Proteina, an open model that combines programmable protein design with search capabilities so scientists and agents can refine designs using constraints and scoring objectives. In reported testing, it achieved higher computational design success rates and throughput than baselines across 4 benchmark suites. Siemens Healthineers is working with NVIDIA on next-generation adaptive radiotherapy using agentic co-planning, patient-specific simulation and robotic control. Automata, Benchling, Danaher and others are using the BioNeMo platform to build scientific agents that link drug design, autonomous labs and biological discovery. Projections show about 35 million people worldwide will be diagnosed with cancer each year by 2050.
- Rapid Micro Biosystems to Participate at the PDA Pharmaceutical Microbiology Conference 2026
Rapid Micro Biosystems (Nasdaq: RPID) said it will sponsor the PDA Pharmaceutical Microbiology Conference 2026 in Washington, D.C., October 26-28, and invites visitors to Booth 101. Its Growth Direct platform will be featured in a presentation by Sophia Pfeiffer of Boehringer Ingelheim on Monday, October 26 at 1:10 p.m. ET, covering early detection of mold contamination using computer vision and AI. The company describes Growth Direct as an industry-leading, fully automated, non-destructive, growth-based platform for microbial quality control testing.
- UMass Memorial Health Announces Unified Data Platform Multi-Year Initiative, Investments in AI-Powered Innovation in Partnership with Accenture and Microsoft
UMass Memorial Health announced a multi-year initiative with Accenture (NYSE: ACN) and Microsoft to modernize its data platform, supporting care delivery, operations and AI-powered innovation. A unified platform on Microsoft Azure will replace siloed reporting systems, bringing the electronic health record and clinical, operational and research data into one connected platform. Accenture will introduce agentic AI tools to automate complex workflows, with goals including shorter patient length of stay and less administrative burden for caregivers. The transformation is expected to improve speed, quality and security while lowering long-term infrastructure costs, and to support greater data sharing and research with UMass Chan Medical School.
- Moderna's Stock Just Stumbled. Is It a Buy on the Dip?
Moderna shares fell 17% in one session after leaked data from a phase 3 trial of intismeran autogene combined with Merck's Keytruda, though the leaked results showed the drug combo cut the risk of recurrence or death by 42% in certain melanoma patients versus Keytruda alone, and by 58% after six months. The stock has still climbed more than 500% this year, trading near $200 versus an average Wall Street 12-month price estimate of $135. The author sees the dip as possibly a buying opportunity for long-term investors who want to open or add to a position, while cautioning that the stock remains sensitive to trial data and may see further pullbacks. Moderna currently has four commercialized products in the U.S., all respiratory vaccines.
- Why Healthcare ETFs Are Hovering Around One-Year Highs
Healthcare ETFs are near one-year highs, supported by an improving earnings outlook, positive trial data, relatively attractive valuations, and a shift out of crowded AI/tech trades. The State Street Health Care Select Sector SPDR ETF (XLV) rose 23.2% over six months (as of Oct. 20, 2026), versus about 9.2% for the State Street SPDR S&P 500 ETF Trust (SPY). S&P 500 healthcare companies are expected to post double-digit earnings growth from Q4 2026 through 2027, and sector M&A value has reached nearly $284 billion this year, approaching 2025's $306 billion. Notable 2026 readouts include Eli Lilly's retatrutide (28.3% average weight loss over 80 weeks at the 12-mg dose) and Vertex's povetacicept (49.8% proteinuria reduction vs. placebo at Week 36). The article also profiles the VanEck Biotech ETF (BBH, up 30.8% YTD) and Invesco Biotechnology & Genome ETF (PBE, up 20.5% YTD).
- Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy?
The article compares two healthcare ETFs: PJP, which focuses on pharmaceutical companies, and IBB, which spans 243 biotechnology stocks. IBB has the lower expense ratio at 0.44% versus 0.58% for PJP, while PJP pays higher dividends, $1.13 per share over the trailing 12 months compared with $0.34 for IBB. IBB had a max drawdown of nearly 40% during the 2022 bear market and has a higher beta, indicating more volatility, though it has outperformed PJP over the past year as biotech stocks surged in 2026. PJP has been more stable and has outperformed IBB over five years, with a smaller max drawdown and lower beta. The article concludes that the right choice depends on each investor's goals and risk tolerance.
Related markets
Latest news
- Blackstone's $2.3 Billion CoreWeave Bet Sparked a Trillion-Dollar AI Lending Boom
In 2023, Blackstone executives asked CoreWeave what a GPU is and whether AI is real. Three years later, the $2.3 billion financing Blackstone helped arrange has become the blueprint for a chip-backed lending market.
- TikTok U.S. hunts for multiple gigawatts of computing capacity, sources tell CNBC
TikTok USDS Joint Venture, which operates TikTok in the U.S., is looking to secure multiple gigawatts of computing capacity, according to sources told CNBC. One source said the target is four gigawatts of compute power by the early 2030s. A spokesperson said the platform runs primarily on Oracle Cloud Infrastructure, which will remain its primary cloud provider. The joint venture, established in 2026 under a U.S. executive order requiring divestiture from ByteDance, has three managing investors, Silver Lake, Oracle and MGX, each holding 15%, while ByteDance retains 19.9%.
- Prediction: Amazon Could Double by 2030 if This Part of Its Business Delivers
AWS revenue reached $42.23 billion in Q2 FY26, up 37% year over year and its fastest growth in 18 quarters, yet Amazon shares at $262.59 sit below their 52-week high of $287.20. Amazon raised its 2026 capex estimate to roughly $220 billion from about $200 billion, citing higher memory costs, and free cash flow was -$7.6 billion on a trailing basis. The article's five-year base case puts shares at $489.98 by October 2030, while the consensus target is $331.46. Reaching $500 would require a 90.4% gain, implying a forward P/E of 47x on consensus FY2027 EPS of $10.5519. The author calls the target ambitious but credible if AWS keeps growing above 30%, AI margins follow the core cloud path, and revenue outpaces capex; a recession hitting enterprise cloud budgets is the main risk.
- Gemini Latest Stock Portfolio: Top 4 Stock Picks
Brokerages including Robinhood and Webull let customers link portfolios to AI agents, and Moomoo estimates about 20% of its trading volume could come from agents by year-end, per The Wall Street Journal. In the Rallies AI Arena, where ChatGPT, Claude, Gemini and Grok each manage a $100,000 portfolio, Gemini is up 26% since late November, versus 13.9% for the S&P 500 over the same period, as of Oct. 20. The article profiles Gemini's four holdings, including Intuitive Surgical (11.7% of the portfolio, up 2.2% since purchase) and ServiceNow (9.4%, up 68.7%, its best result). A NBER working paper found AI models' investment strategies did not beat passive benchmarks, and researchers warned that agents using the same data could crowd into the same trades.
- AMD or Broadcom: If I Could Only Own 1 AI Chip Stock Through 2030, Here's My Pick
AMD and Broadcom have both benefited from the AI boom, with AMD shares up 421% and Broadcom up 285% over three years. In Q2, AMD's revenue rose 50% year over year to $11.5 billion, its data center segment reached $6.7 billion (up 107%), and non-GAAP EPS hit $1.66 (up 246%), with AMD projecting a $220 billion CPU opportunity and a $1.4 trillion AI accelerator opportunity by 2030. Broadcom's fiscal Q3 2026 revenue grew 86% to $29.6 billion, with AI semiconductor revenue up 221% to $16.7 billion, and it projects $115 billion in AI revenue for fiscal 2027 and $230 billion for fiscal 2028. The author gives a slight edge to Broadcom on valuation, at 19.4x forward earnings versus 39.5x for AMD, though AMD's EPS is growing faster. Broadcom's margins could decline as lower-margin AI chip sales take a larger share of its total revenue.
- AI's 'Black October': Critical PHP flaws set off global security scramble
Cybersecurity teams worldwide are rushing to patch critical flaws in PHP, a language some estimates say is used by nearly 70% of websites. Researchers at Google's Wiz and AI firm Calif found the major vulnerabilities in August using advanced AI models from OpenAI and Google, and as warnings spread, governments and businesses scrambled to respond. Figma's John Milinovich said several dozen cyberattacks in just two days would each have been the worst of an entire year, while Anthropic's Jason Clinton warned the landscape will likely get “a lot worse” and that the sector must hold on for about 18 months. Former director of the U.S. Cybersecurity and Infrastructure Security Agency Chris Krebs said smaller businesses may struggle to fix serious bugs, and noted that 3% of all critical vulnerabilities ever discovered were found in the past month.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.